Get the Stockscreener App
4.72
0.21%
0.010
After Hours:
4.72
Trisalus Life Sciences Inc stock is traded at $4.72, with a volume of 31,457.
It is up +0.21% in the last 24 hours and down -9.06% over the past month.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
See More
Previous Close:
$4.71
Open:
$4.8
24h Volume:
31,457
Relative Volume:
0.43
Market Cap:
$178.60M
Revenue:
$15.33M
Net Income/Loss:
$-40.19M
P/E Ratio:
-2.6938
EPS:
-1.7522
Net Cash Flow:
-
1W Performance:
-5.60%
1M Performance:
-9.06%
6M Performance:
-4.26%
1Y Performance:
-17.05%
1-Day Range:
$4.71
$4.8384
1-Week Range:
$4.62
$5.03
52-Week Range:
$3.50
$6.04
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
Name
Trisalus Life Sciences Inc
Sector
Industry
Phone
415 336 8917
Address
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
4.72 | 189.88M | 15.33M | -40.19M | 0 | -1.7522 |
|
ABT
Abbott Laboratories
|
120.51 | 232.44B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.65 | 153.66B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
388.90 | 150.87B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
89.53 | 114.55B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.18 | 46.22B | 5.54B | 4.18B | 623.10M | 7.00 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Initiated | Lake Street | Buy |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-11-24 | Initiated | ROTH MKM | Buy |
| Oct-25-24 | Initiated | Northland Capital | Outperform |
| Sep-16-24 | Initiated | Oppenheimer | Outperform |
| May-30-24 | Initiated | Canaccord Genuity | Buy |
View All
Trisalus Life Sciences Inc Stock (TLSI) Latest News
SNRG(synergy) News and UpdatesDouble Your Capital Alerts - Newser
CRTS(cratos)Free Investment Risk Control - Newser
Why Plum Acquisition Corp. IV Equity Warrant stock attracts strong analyst attentionReturn Maximized Portfolio Strategy - Newser
Why CKPT stock attracts strong analyst attentionHigh Potential Stock Ideas - Newser
Why ABVE stock attracts strong analyst attentionSafe and Smart Investment Picks - Newser
Scalable AI based quantum solutions for deep learning model deploymentProtected Capital Trading Plan - Newser
How TriSalus Life Sciences Inc. Equity Warrant stock performs during market volatilityMulti Bagger Alerts - Newser
How BCSF stock performs during market volatilityMassive Profit Potential - Newser
What makes Royce Micro Cap Trust Inc. stock price move sharplyMomentum Swing Watchlist - Newser
What makes TriSalus Life Sciences Inc. Equity Warrant stock price move sharplyMassive Upside Selection - Newser
How ITUB stock performs during market volatility3x Return Stock Radar - Newser
Why TriSalus Life Sciences Inc. Equity Warrant stock attracts strong analyst attentionFree Professional Trading Signals - Newser
How TriSalus Life Sciences Inc. stock performs during market volatilityRisk Aware High Growth Picks - Newser
What makes TriSalus Life Sciences Inc. stock price move sharplyDaily Gain Forecast - Newser
Why TriSalus Life Sciences Inc. stock attracts strong analyst attentionLow Risk Trade Timing Signals - Newser
How Sonder Holdings Inc. Equity Warrant stock performs during market volatilityFree Stock Market Strategy Classes - Newser
What makes OppFi Inc. stock price move sharplyReal Time Alert Service - Newser
IWN ETF Implied Analyst Target Price: $198.15 - AInvest
How ABLVW stock performs during market volatilityFree Access to Group - Newser
Why SES.WS stock attracts strong analyst attentionSolid Return Trade Selections - Newser
What makes LXEH stock price move sharplyFree Premium Stock Market Reports - Newser
Why Scholastic Corporation stock attracts strong analyst attentionFree Low-Risk Investment Plans - Newser
Freelance as a web developer for eCommerce and digital business websitesWeekly Big Movers - Newser
Analysts Are Bullish on These Healthcare Stocks: Evaxion Biotech (EVAX), CVRx (CVRX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Gain Therapeutics (GANX) and Edwards Lifesciences (EW) - The Globe and Mail
Absci Appoints Biopharma Leader Mary Szela to Board of Directors - The Manila Times
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
TriSalus Life Sciences launches preferred stock exchange - MSN
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure - Bluefield Daily Telegraph
TriSalus Life Sciences (NASDAQ:TLSIW) Stock Price Down 7.1% – Should You Sell? - Defense World
BENJI(basenji) Price TodaySteady Profit Stock Forecasts - Newser
TriSalus shareholders elect directors, ratify auditor By Investing.com - Investing.com South Africa
TriSalus shareholders elect directors, ratify auditor - Investing.com
TriSalus Life Sciences Holds Annual Shareholder Meeting - TipRanks
Equities Analysts Set Expectations for TLSI FY2026 Earnings - Defense World
Cantor Fitzgerald maintains $9 target on TriSalus stock By Investing.com - Investing.com Nigeria
Millennium Management LLC Cuts Holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) - Defense World
Cantor Fitzgerald maintains $9 target on TriSalus stock - Investing.com
Bank of America Corp DE Raises Holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) - Defense World
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
TriSalus Launches TriNav FLX To Enhance Drug Delivery In Complex Peripheral Vessels - Nasdaq
TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System - Bluefield Daily Telegraph
TriSalus Unveils Next-Gen Cancer Treatment Device: New TriNav FLX Shows 28% Better Navigation - Stock Titan
Northern Trust Corp Has $161,000 Position in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) - Defense World
Cantor Fitzgerald maintains TriSalus stock rating after CFO change By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains TriSalus stock rating after CFO change - Investing.com
TriSalus Life Sciences names new CFO - BizWest
TriSalus Life Sciences (TLSI) Plans to Offer 5.5M Shares of Comm - GuruFocus
Trisalus Life Sciences Inc Stock (TLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.67%
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):